Areas of Interest

Collaborative Vision

At Lilly Research Laboratories, we continue to build our rich pipeline and product portfolio. Approximately 8,000 scientists and other professionals are engaged in research and development. We conduct clinical research in more than 50 countries, and we have R&D facilities in 8 countries.

To complement our current efforts, we seek novel products across a diverse set of therapeutic platforms—along with new research, technology, and capabilities that will help us develop and deliver highly effective treatments to patients.

And while historically we have excelled in small-molecule therapeutics, our large-molecule/biotechnology efforts are growing rapidly. (Biotech is far from new for Lilly; in fact, insulin—the drug that helped firmly establish the company—was an alliance-based biotech product.) In addition to Humulin® and Humatrope®, our portfolio now includes biotech molecules such as Byetta®, Forteo®, and Xigris®, and 2007 sales in this area totaled $4.56 billion. Biotherapeutics represent about one-third of our pipeline.

Our areas of interest are focused mainly on first-in-class or best-in-class medicines and include:

Oncology

• Targeted cancer therapies
• Novel predictive biomarkers
• Drug formulations and combinations that provide clear medical benefit advantages and differentiation

Neuroscience

• Innovative clinical and preclinical approaches related to psychiatry, neurology as well as pain and migraine
• Novel predictive biomarkers

Cardiovascular

• Innovative clinical and preclinical approaches focused in atherosclerosis, metabolic syndrome, coronary ischemia, and hypertension
• Novel predictive biomarkers

Endocrinology

• Innovative approaches, including targets, for type 1 and 2 diabetes and obesity
• Novel insulin approaches
• Novel biomarkers for measurement of beta cell mass and function as well as efficacy assessment of anti-obesity treatments

Musculoskeletal

• Novel clinical and preclinical therapies for the treatment of osteoporosis, frailty, and arthritis
• Novel druggable targets for the treatment of osteoporosis, osteoarthritis, and muscle loss/frailty
• Novel predictive biomarkers

Other areas of interest

• Inflammatory/auto-immune diseases
• Key women’s health issues
• Anemia
• Irritable Bowel Syndrome
• Areas of high unmet medical need

Technologies driving development across the R&D value chain

• Biology
• Biomarkers
• Chemistry
• Drug delivery
• Informatics
• Pharmacology
• Toxicology